Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

被引：0
|
作者：
Haricharan, Svasti [1 ]
Punturi, Nindo [1 ]
Seker, Sinem [1 ]
Devarakonda, Vaishnavi [2 ]
Kalra, Rashi [2 ]
Chen, Ching-Hui [2 ]
Mazumder, Aloran [1 ]
Li, Shungqiang [3 ]
Primeau, Tina [3 ]
Ellis, Matthew [2 ]
Kavuri, Shyam [2 ]
机构：
[1] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Washington Univ, St Louis, MO 63110 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD8-05
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
    Punturi, Nindo B.
    Seker, Sinem
    Devarakonda, Vaishnavi
    Mazumder, Aloran
    Kalra, Rashi
    Chen, Ching Hui
    Li, Shunqiang
    Primeau, Tina
    Ellis, Matthew J.
    Kavuri, Shyam M.
    Haricharan, Svasti
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [2] Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
    Nindo B. Punturi
    Sinem Seker
    Vaishnavi Devarakonda
    Aloran Mazumder
    Rashi Kalra
    Ching Hui Chen
    Shunqiang Li
    Tina Primeau
    Matthew J. Ellis
    Shyam M. Kavuri
    Svasti Haricharan
    Nature Communications, 12
  • [3] A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
    Yang, Xue
    Smirnov, Artem
    Buonomo, Oreste Claudio
    Mauriello, Alessandro
    Shi, Yufang
    Bischof, Julia
    Woodsmith, Jonathan
    TOR CENTRE, Francesca
    Melino, Gerry
    Candi, Eleonora
    Bernassola, Francesca
    CELL DEATH DISCOVERY, 2023, 9 (01)
  • [4] A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
    Xue Yang
    Artem Smirnov
    Oreste Claudio Buonomo
    Alessandro Mauriello
    Yufang Shi
    Julia Bischof
    Jonathan Woodsmith
    Gerry Melino
    Eleonora Candi
    Francesca Bernassola
    Cell Death Discovery, 9
  • [5] HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer
    Mazumder, Aloran
    Shiao, Stephen
    Haricharan, Svasti
    ENDOCRINOLOGY, 2021, 162 (10)
  • [6] Activating HER2 missense mutations in HER2-negative metastatic breast cancer
    Shah, Mirat
    Ensminger, Jennifer
    Wang, Chenguang
    Ali, Siraj
    Chung, Jon
    Lauring, Josh
    Park, Ben Ho
    Stearns, Vered
    CANCER RESEARCH, 2020, 80 (04)
  • [7] HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients
    Endo, Yumi
    Dong, Yu
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Yamashita, Hiroko
    Sato, Shinya
    Takahashi, Satoru
    Fujii, Yoshitaka
    Toyama, Tatsuya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (07) : 619 - 623
  • [8] HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
    Landmann, Alessandra
    Farrugia, Daniel J.
    Diego, Emilia
    Bonaventura, Marguerite
    Soran, Atilla
    Johnson, Ronald
    Dabbs, David J.
    Clark, Beth
    Brufsky, Adam
    Davidson, Nancy E.
    Lembersky, Barry C.
    Jankowitz, Rachel Catherine
    Puhalla, Shannon
    Ahrendt, Gretchen M.
    McAuliffe, Priscilla F.
    Bhargava, Rohit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
    Miles, David W.
    BREAST CANCER RESEARCH, 2009, 11 (04)
  • [10] Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
    Burguin, Anna
    Furrer, Daniela
    Ouellette, Genevieve
    Jacob, Simon
    Diorio, Caroline
    Durocher, Francine
    PLOS ONE, 2020, 15 (06):
12345